rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Cytotoxic payloads for antibody--drug conjugates
  name:
    name part: Thurston, David E.
    role:
      role term: creator
    role:
      role term: editor.
  name:
    name part: Jackson, Paul J. M.
    role:
      role term: editor.
  type of resource: text
  genre: Electronic books.
  origin info:
    place:
      place term: enk
    date issued: 2019
    copyright date: 2019
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource
  abstract: Antibody-drug conjugates are a promising areas of anticancer drug discovery, conveying several advantages, including the ability to select likely responders, efficient delivery of cytotoxic agents and reduced toxicity. This book describes payloads used to date and novel payloads that may be used clinically in the future.
  table of contents: Cover; Cytotoxic Payloads for Antibody-Drug Conjugates; Preface; Contents; Chapter 1 -- Introduction to Antibody-Drug Conjugates (ADCs); 1.1 Introduction to Cancer; 1.2 Cancer Treatments; 1.3 Antibody-Drug Conjugates (ADCs); 1.3.1 Mechanism of Action of ADCs; 1.3.2 Antibody Selection; 1.3.3 Linker Design; 1.3.3.1 Cleavable Linkers; 1.3.3.2 Non-cleavable Linkers; 1.3.4 Payload Selection; 1.3.5 Conjugation of Payload; 1.3.5.1 Conjugation via Lysine Residues; 1.3.5.2 Conjugation via Thiol Groups; 1.3.5.3 Site-specific Conjugation; 1.3.5.4 Click Chemistry for Conjugation
  table of contents: 1.3.5.5 Other Types of Conjugation1.3.6 Analytical Characterisation of ADCs; 1.3.6.1 Drug to Antibody Ratio (DAR); 1.3.6.2 Determination of Unconjugated Payload Content in an ADC; 1.3.6.3 Hydrophobicity Prediction; 1.4 Conclusions; References; Chapter 2 -- Design Factors Important for Antibody-Drug Conjugate (ADC) Payloads; 2.1 Introduction; 2.2 The Challenges in Making Effective ADCs; 2.3 Distribution of ADCs into Tumour Tissue; 2.3.1 Diffusion and Extravasation of ADCs; 2.3.2 Effect of Linker-Payload on ADC Distribution into Tumour Tissue
  table of contents: 2.3.3 The Effect of Target Antigen Density on ADC Distribution2.4 Retention of ADCs by Tumour Tissue; 2.5 Uptake and Metabolism of ADCs by Cancer Cells; 2.5.1 Release of Cytotoxic Payload in Tumour Tissue; 2.5.2 Trafficking and Release of Cytotoxic Payload in Tumour Tissue; 2.5.3 Payload Metabolites and Bystander Killing; 2.6 Design Factors Important for the Safety of ADCs; 2.7 ADCs and the Tumour Microenvironment; 2.8 Summary; Acknowledgements; References; Chapter 3 -- Use of Molecular Modelling Techniques in Antibody-Drug Conjugate (ADC) Payload Discovery and Development; 3.1 Introduction
  table of contents: 3.2 Molecular Modelling of MMAE/MMAF Payloads3.3 Molecular Modelling of C8-linked Pyrrolobenzodiazepines (PBDs); 3.3.1 Molecular Modelling Studies of C7-linked PBD Dimers; 3.3.2 Molecular Modelling of C8/C2-linked and C2/C2-linked PBD Dimers; 3.4 Conclusion and Future Perspective; References; Chapter 4 -- Auristatin Payloads for Antibody-Drug Conjugates (ADCs); 4.1 Discovery of the Auristatins; 4.2 Mechanism of Action; 4.3 Activity; 4.4 Synthetic Availability and Analogues; 4.5 Validation of Auristatins Payloads for ADC Technology; 4.5.1 Auristatin E and Related Conjugates
  table of contents: 4.5.2 Development of Brentuximab Vedotin (ADCETRIS)4.5.3 More MMAE Conjugates; 4.5.4 Novel Linker Technologies; 4.5.5 Extending the Range of Auristatin E- type Molecules; 4.6 Development of Monomethyl Auristatin F; 4.6.1 MMAF Properties; 4.6.2 Development of Alternative Ways of Linking MMAF to an Antibody; 4.6.3 C-Terminus- linked Auristatin F Conjugates; 4.7 Conclusions; References; Chapter 5 -- Maytansinoid Payloads for Antibody-Drug Conjugates (ADCs); 5.1 Introduction; 5.2 Maytansinoids: Structure-Activity Relationships (SARs); 5.3 Synthesis of Maytansinoid-ADCs
  note: edited by David E. Thurston and Paul J.M. Jackson.
  subject:
    topic: Antibody-drug conjugates
  subject:
    topic: Antineoplastic agents
  subject:
    topic: Antibody-drug conjugates
  subject:
    topic: Antineoplastic agents
  subject:
    topic: MEDICAL
    topic: Oncology
  classification: RS201.A56
  classification: 615.37
  related item:
    title info:
      title: Cytotoxic payloads for antibody--drug conjugates
    name:
      name part: Thurston, David E.
    origin info:
      publisher: Cambridge : Royal Society of Chemistry, [2019]
    identifier: (OCoLC)1044807367
  related item:
    title info:
      title: RSC drug discovery series ; 71
  identifier: 1788012895
  identifier: 1788018451
  identifier: 9781788012898
  identifier: 9781788018456
  identifier: 1788010779
  identifier: 9781788010771
  identifier: 5049:4901 Royal Society of Chemistry
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: N$T
    record creation date: 190724
    record change date: 20210304144556.0
    record identifier: in00004356354
    language of cataloging:
      language term: eng